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Abstract
Background: We previously reported no benefit of early weaning for HIV-free survival of children born to HIV-infected
mothers in intent-to-treat analyses. Since early weaning was poorly accepted, we conducted a secondary analysis to
investigate whether beneficial effects may have been hidden.
Methods: 958 HIV-infected women in Lusaka, Zambia, were randomized to abrupt weaning at 4 months (intervention) or to
continued breastfeeding (control). Children were followed to 24 months with regular HIV PCR tests and examinations to
determine HIV infection or death. Detailed behavioral data were collected on when all breastfeeding ended. Most
participants were recruited before antiretroviral treatment (ART) became available. We compared outcomes among mother-
child pairs who weaned earlier or later than intended by study design adjusting for potential confounders.
Results: Of infants alive, uninfected and still breastfeeding at 4 months in the intervention group, 16.1% who weaned as
instructed acquired HIV or died by 24 months compared to 16.0% who did not comply (p=0.98). Children of women with
less severe disease during pregnancy (not eligible for ART) had worse outcomes if their mothers weaned as instructed
(RH=2.60 95% CI: 1.06–6.36) compared to those who continued breastfeeding. Conversely, children of mothers with more
severe disease (eligible for ART but did not receive it) who weaned early had better outcomes (p-value interaction=0.002).
In the control group, weaning before 15 months was associated with 3.94-fold (95% CI: 1.65–9.39) increase in HIV infection
or death among infants of mothers with less severe disease.
Conclusion: Incomplete adherence did not mask a benefit of early weaning. On the contrary, for women with less severe
disease, early weaning was harmful and continued breastfeeding resulted in better outcomes. For women with more
advanced disease, ART should be given during pregnancy for maternal health and to reduce transmission, including
through breastfeeding.
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Introduction
Global public health recommendations advise exclusive
breastfeeding for the first six months of life followed by
introduction of nutritionally-adequate complementary foods
while breastfeeding continues to two years or beyond [1]. For
infants of HIV-infected mothers, however, mathematical models
have estimated that there may be benefits of shortening the
usual duration of breastfeeding [2,3] and several studies have
observed ongoing risks of HIV transmission with continued
breast milk exposure regardless of the child’s age [4–7]. These
findings prompted several authors to suggest that early weaning
may be advisable for HIV-infected women [4–7]. None of
these studies has taken into account the competing risks of
uninfected child mortality as a result of early termination of
breastfeeding.
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6059We conducted a randomized clinical trial in Lusaka, Zambia, of
a counseling program to encourage early weaning at 4 months of
age to determine the effects of this intervention on HIV-free
survival of infants born to HIV-infected mothers [8]. Although we
expected that early weaning would be beneficial, there were no
empirical data to support this belief at the time we started the trial.
In final intent-to-treat analyses, no benefit of early weaning for
HIV-free survival was observed [9]. Since early weaning was
poorly accepted by the study population despite intensive
counseling and support to encourage it, some have argued that
incomplete adherence may have masked a true benefit of the
intervention [10]. Here we present secondary analyses to
investigate the consequences of incomplete adherence for
inferences about the effects of early weaning, comparing outcomes
among mother-child pairs in the intervention and control groups
who stopped breastfeeding earlier or later than intended by the
study design.
Methods
Study design
The study was an un-blinded, randomized trial of a behavioral
intervention among HIV-infected women to encourage exclusive
breastfeeding with abrupt cessation of breastfeeding at 4 months
compared to standard practice [8]. In brief, HIV-infected women
were recruited from two antenatal clinics in Lusaka, Zambia and
received single-dose nevirapine prophylaxis [11,12]. Between May
2001 and September 2004, 1435 pregnant, HIV-seropositive
women who intended to breastfeed were recruited. Women still
breastfeeding at 1 month post-partum (n=958) were randomized
to one of two groups. Randomization assignment was prepared by
the study statistician and was accessed through a computer
program. In the intervention group, women were encouraged to
breastfeed exclusively to 4 months and then to stop breastfeeding
abruptly. Preparation for early weaning began around two months
with education, counseling and encouragement to express breast
milk and practice cup feeding prior to weaning. A three-month
supply of infant formula and a fortified weaning cereal was
provided and training and education to make replacement feeding
as safe as possible was done. In the control group, women were
encouraged to exclusively breastfeed to 6 months, gradually
introduce complementary foods (not provided) and continue to
breastfeed for a duration of their own informed choice. All women
provided written informed consent. The study was approved by
Human Subjects Committees at the institutions of all the authors
in the U.S. and in Zambia. The protocol for this trial and the
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Study procedures
Maternal blood was drawn at enrollment and was tested for
CD4 and CD8 counts (FACSCount, BD Immunocytometry
Systems, San Jose, CA), hemoglobin (HemocueH system, Lake
Forest, CA) and viral load (Roche AmplicorH 1.5, Roche,
Branchburg, NJ). Most women did not receive antiretroviral
therapy (ART) for their own health as HIV treatment only became
available in the public sector after May 2004 [13]. However,
because data on CD4 count and clinical staging were collected at
enrollment, we classified women retrospectively as having severe
disease requiring ART if their CD4 count was ,200 cells/mLo ri f
their CD4 count was 200–349 cells/mL and they had WHO stage
III or greater clinical disease. If women did not meet these criteria
they were classified as having less severe disease. Cotrimoxazole
was given to women with CD4 counts ,200 after November 2003
[14]. Sociodemographic and clinical data were collected at
enrollment and obstetric/neonatal data after delivery. Infant
heelstick blood samples were collected onto filter paper on the day
of birth, at 1 week, and at 1, 2, 3, 4, 4 K, 5, 6, 9, 12, 15, 18, 21,
and 24 months of age. Samples were tested in batches for HIV-1
DNA by PCR [15]. All positives were confirmed $2 samples if
available, and, if not, the same sample was re-tested to confirm. To
rule out false negative test results due to inadequate samples,
amplification of the beta-globin gene was performed. Growth
monitoring was done monthly and children from either group with
evidence of failure-to-thrive were provided with nutrition
supplements. Cotrimoxazole was given to all infants (infected
and uninfected) between 6 weeks and 12 months. Home visit
teams tracked participants who did not return for appointments.
Information about child deaths was sought from hospital and clinic
records and interviews with caretakers and health care personnel.
Circumstances of all deaths were reviewed to identify causes of
death. A standardized questionnaire was administered at every
study visit by a member of the study team who was not conducting
the feeding counseling to determine feeding behaviors in the past
24 hours, past week and since the last visit.
Statistical methods
The analysis was restricted to 661 mother-child pairs who
survived uninfected and still breastfeeding to 4 months. Since
practices were intentionally the same in the two groups before this
time, focus on the post-4 month time period provides the clearest
investigation of the effects of actual behaviors on outcomes.
Breastfeeding duration was determined based on the exact age
that breastfeeding was first reported to have completely stopped.
Children who died were assumed to have been breastfed up to
their death date unless reports indicated that it ceased prior to the
illness preceding the child’s death. The primary outcome was HIV
infection or death which was examined using Kaplan-Meier life-
table methods for univariate and Cox Proportional Hazards
models for multivariate analyses [16]. For HIV infection, the
midpoint between the last negative and first positive PCR test was
imputed as the event time, for deaths the actual age of death was
used.
First, we examined the outcome (HIV infection or death) only in
the intervention group stratifying by a fixed covariate to compare
those who adhered to the intervention (defined as stopping
breastfeeding by the completion of 4 months) vs. those who did not
adhere (i.e. continued breastfeeding for 5 or more months). Other
variables thought to be possible confounders or effect modifiers
(maternal CD4 count, viral load, hemoglobin, body mass index,
eligibility for ART, age, parity, RPR status, disclosure, education,
marital status, domestic electricity, water source, cooking method,
household crowding, other children in the home, past history of
child deaths, employment, food security, compliance with
nevirapine prophylaxis and child sex and birth weight) were
entered into a Cox Proportional Hazards model on their own,
with each other, and as possible effect modifiers of feeding
practice. Variables that were significantly associated with the
outcome or which changed the magnitude of the association
between feeding practice and the outcome by more than 10%
were retained in final multivariable models. Follow-up time was
censored at the time women initiated ART.
Second, we restricted analyses to the control group and
examined associations between the outcome (HIV infection or
death) and breastfeeding cessation (weaning) as a time-dependent
variable over the full duration of follow-up (24 months).
Investigation of confounding and effect modification was done as
in the intervention group.
HIV-Free Survival and Weaning
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major effect modifier, we conducted further analyses to identify an
age when weaning would be ‘‘safe’’ We defined ‘‘safe’’ as the age
when the weaning hazard ratio (HR) was less than or equal to 1.
Combining data from both groups and restricted to those with less
severe disease, we ran a Cox Proportional hazard model with one
time-dependent covariate equal to 1 if weaning occurred ,365
days (0 otherwise – var 1), and a second time-dependent covariate
equal to 1 if weaning occurred 365–730 days (0 otherwise – var 2),
and a multiplicative interaction term between the time-dependent
covariate for weaning 365–730 days and child age of weaning (var
3). It was necessary to have two time-dependent terms for weaning
since the HR associated with weaning increased with child age up
to 12 months. To determine the exact child age when the HR
reached 1 (i.e. no longer increased the risk of HIV infection or
death), we took the ratio of the Cox model b coefficients for var 2
and var 3 i.e. b2/b3. This formula can be derived from the Cox
model equation since e
b=HR or b=0 when HR=1 [16].
Utilizing this optimal age for weaning, we followed the same
approach to identify a CD4 count threshold when weaning would
be ‘‘safe.’’ Combining results from both groups and including
women with both less and more severe disease, we ran a Cox
model with CD4 count as a continuous variable (var 4), a time-
dependent covariate equal to 1 if weaning occurred before the
optimally selected age (0 otherwise – var 5), and a multiplicative
interaction term between weaning and CD4 count (var 6). To
estimate the exact CD4 count when the weaning HR crossed over
from being beneficial (i.e. reducing the risk of HIV infections or
deaths) to being harmful (i.e. increasing the risk of HIV infections
or death), we took the ratio of b5/b6.
To describe differences between groups, categorical character-
istics were tested using chi-squared tests, normally-distributed
continuous variables using t-tests, non-normal continuous vari-
ables using Wilcoxon tests and time to event variables using log-
rank tests. To compare breastfeeding duration between groups, we
treated breastfeeding as a time-to-event variable with weaning as
the event and censoring pairs who were lost or died while still
breastfeeding. Kaplan-Meier life-table methods were used for
univariate and Cox Proportional Hazards models for multivariate
analyses [16]. All analyses were done using SAS version 9.2 (Cary,
NC).
Results
Study population
Of 958 mother-child pairs randomized, 328/481 (68.2%) in the
intervention and 333/477 (69.8%) in the control group were alive,
HIV uninfected (HIV negative PCR at $4 months) and still
breastfeeding at 4 months. In the intervention group of those still
breastfeeding at 4 months, 60.9% stopped breastfeeding by the
completion of 4 months (as dictated by the study protocol) vs.
2.1% among the controls. The median duration of breastfeeding
was 4.4 months (inter-quartile range [IQR] 4.2–15 months) in the
intervention and 16 months (IQR 12–19 months) in the control
group (p,0.001).
Effects of adherence in the intervention group
There was no significant difference in the rate at which children
of mothers who adhered to the intervention and weaned by the
end of 4 months acquired HIV infection or died by 24 months
(16.1%) compared to those who were non-adherent and continued
breastfeeding (16.0% p=0.98). If person-time was censored at the
time of ART initiation, the rates of HIV infection or death by 24
months were 16.2% among those who weaned at 4 months vs.
14.2% among those who continued breastfeeding for longer
(p=0.64). There were some differences between mother-child
pairs who adhered to the intervention counseling (Table 1) but
median CD4 counts and viral loads were not significantly different
between those mothers who adhered (348 cells/ml and 33,360
copies/ml) vs. those who did not (373 cells/ml and 27,972 copies/
ml, respectively).
There was significant effect modification by the severity of
maternal disease. Children of women with less severe disease
during pregnancy had significantly worse outcomes if their
mothers were adherent and weaned early compared to infants
whose mothers were non-adherent and continued breastfeeding
(RH=2.40 95% CI: 1.04–5.54). In contrast, children born to
women with advanced HIV disease had significantly better
outcomes if their mothers were adherent (Figure 1). The
interaction was significant (p=0.001) and early weaning remained
associated with a more than 2-fold increase in the risk of HIV
infection or death (RH=2.60 95% CI: 1.06–6.36, p=0.036)
among infants born to mothers with less severe disease even after
adjusting for maternal hemoglobin, body mass index, parity, and
birth weight. No other factors met criteria for inclusion in final
multivariable models.
The differential effects of early weaning by the severity of
maternal disease were explained by low rates of HIV transmission
and elevated uninfected child mortality due to weaning among
women with less severe disease. Among women with less advanced
disease, HIV transmission rates were low regardless of whether or
not early weaning was practiced (5.0%) or not (3.9%) but
uninfected child mortality rates were significantly higher among
children whose mothers adhered to the intervention (14.8%)
compared to those who did not (4.7%). As a result there was net
harm associated with adherence with the intervention among
infants born to mothers with less severe disease. Among women
with advanced disease, HIV transmission rates were significantly
lower among those who weaned early (5.5%) compared to those
who continued to breastfeed (25.6%) and, in this group, uninfected
child mortality was not affected by weaning practice, resulting in a
net benefit associated with adherence with the intervention
(Table 2).
Effects of spill-over in the control group
Breastfeeding duration in the control group (median 16 months)
was shorter than expected based on reported behaviors during the
prior pregnancy (median 18 months). Weaning before 4 months
was rare (2.1%) but cessation before 12 months (21.4%) was more
frequent than reported for the previous pregnancy (13.5%).
Factors associated with the duration of breastfeeding in the
control group are shown in Table 3. More education and the
availability of water and electricity were associated with shorter
breastfeeding.
Consistent withthe resultsintheinterventiongroup,a statistically
significant interaction (p=0.01) between breastfeeding cessation
and severity of maternal disease was detected in the control group.
Among infants of mothers with less severe disease, stopping
breastfeeding before 24 months was associated with .3-fold
increased risk of HIV infection or death (RH=3.41 95% CI:
1.52–7.65, p=0.003) whereas among infants of mothers with more
advanced disease, weaning was not associated with the outcome
adjusting for maternal viral load and child birth weight. No other
factors met criteria for inclusion in final multivariable models.
Thresholds for safer weaning
Among infants born to HIV-infected mothers with less
advanced disease in either randomized group, breastfeeding
HIV-Free Survival and Weaning
PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e6059Table 1. Predictors of adherence (i.e. weaning at 4 months) among 328 mother-child pairs randomized to the intervention group
surviving HIV-free and still breastfeeding at 4 months.
Characteristic Total N N (%) stopped BF by end of 4 mo p-value
Maternal factors:
CD4 count
,200 60 40 (66.7)
200–349 100 65 (65.0)
$350 cells/mm
3 168 98 (58.3) .0.10
Plasma viral load
#9,999 99 61 (61.6)
10,000–99,999 157 88 (56.1)
$100,000 copies/ml 71 54 (76.1) 0.02
Hemoglobin
,10 79 53 (67.1)
$10 g/dL 246 149 (60.6) .0.10
Classification of severity of disease*
Less severe 229 134 (58.5)
More severe 99 69 (69.7) 0.06
Body mass index 1 month post-partum
,18.5 48 34 (70.8)
$18.5 280 169 (60.4) .0.10
Age (years)
,20 19 14 (73.7)
20–24 115 62 (53.9)
25–29 101 67 (66.3)
$30 93 60 (64.5) .0.10
Parity
First child 39 23 (59.0)
2
nd–3
rd 156 92 (59.0)
$Fourth 133 88 (66.2) .0.10
RPR status
Positive 56 33 (58.9)
Negative 252 163 (64.7) .0.10
Social factors:
Disclosed HIV status to partner 182 113 (62.1)
Not disclosed 146 90 (61.6) .0.10
Marital status
Married 284 175 (61.2)
Single 29 17 (58.6)
Widowed/divorced/separated 15 11 (73.3) .0.10
Education
No school or ,8 years of school 188 107 (52.7)
Some or complete high school ($8 y) 140 96 (68.6) 0.03
Domestic water source
Within dwelling or on property 51 44 (86.3)
Communal 277 159 (57.4) ,0.01
Electricity in the home
Yes 132 87 (65.9)
No 196 116 (59.2) .0.10
Cooking facilities
Stove/hotplate 117 76 (65.0)
Charcoal/wood 211 127 (60.2) .0.10
HIV-Free Survival and Weaning
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longer any excess risk of the combined outcome of HIV infection
or death. Effects of weaning before 15 months were consistent
between the intervention and control groups and remained after
adjusting for potential confounders. In the intervention group,
weaning before 15 completed months was associated with a 3.34–
fold increase in the risk of HIV infection or death (95% CI: 1.16–
9.59) and in the control group a 3.94-fold increase (95% CI: 1.65–
9.39) among those with less severe disease and after adjusting for
confounders (Table 4).
Using as a reference breastfeeding to 15 months, weaning
before 15 months was associated with reduced risk of HIV
infection or death when maternal CD4 counts were low and
increased risk of HIV infection or death when maternal CD4
counts were high (Figure 2). The threshold CD4 count identified
by the data was 306 cells/mL (95% CI: 220–394). In other words,
weaning was protective if women had CD4 counts below this cut-
point, and was harmful if women had higher CD4 counts.
Discussion
All clinical trials with behavioral interventions are vulnerable to
misleading results depending on the degree of adherence. Poor
adherence may dilute the outcomes of a beneficial intervention
leading to the erroneous conclusion of no benefit. However, if an
intervention is harmful, then poor adherence may lead to the
erroneous conclusion that an intervention is safe when it is not.
The primary outcome of our trial was a combination of HIV
infection or uninfected child death and early weaning affects each
of these outcomes differently. The analysis we present here
demonstrates that, after taking into account the dilution
introduced by poor adherence, gains achieved in transmission
reduction due to early weaning were offset by increases in
mortality in the group overall. Hence the original conclusion of no
benefit of early weaning is correct if no distinction is made among
mothers at different stages of HIV progression.
Investigation into possible confounding led us to identify an
interaction between severity of maternal HIV disease during
pregnancy and effects of early weaning. This interaction has
profound implications for infant feeding policies for HIV-infected
women in low resource settings. If infants were born to mothers
with advanced HIV disease, i.e. symptomatic and low CD4
counts, then early weaning resulted in fewer HIV infections or
deaths. If infants were born to mothers with less advanced HIV
disease, i.e. asymptomatic and high CD4 counts, then early
weaning resulted in more adverse clinical outcomes. Since women
with advanced disease should receive ART routinely as part of
HIV treatment services [17], we anticipate that post-natal
transmission should also be reduced. This has been shown in
some demonstration projects [18–20]. Therefore, if access to ART
is in place, there is little justification for shortening the duration of
breastfeeding among mothers with advanced disease. For women
who do not yet need ART according to usual guidelines, our data
indicate that risks associated with transmission are not large
enough to outweigh the substantial increases in uninfected child
mortality that result from prematurely truncating the usual
duration of breastfeeding. For infants of mothers with less severe
disease, weaning at 15 months or earlier is associated with a more
than 3-fold increase in HIV infection or death. Even taking into
account continuing risks of HIV transmission, HIV-free survival is
better if breastfeeding continues for at least 16 months.
There are new data to support proof of concept that
antiretroviral drugs given to the infant during breastfeeding can
reduce postnatal transmission [21,22]. Unfortunately, the studies
investigating this have tested only short interventions [21,22]
premised on the assumption that infants of HIV-infected women
could be safely weaned early. Studies are needed to evaluate
interventions that extend over a full ordinary duration of
breastfeeding.
Alimitationofourstudywasthatadherencewiththe intervention
was incomplete. An advantage of intent-to-treat analysis of
randomized controlled trials is that confounders associated with
the practice of interest are less likely to explain associations.
However, substantial lack of adherence with an intervention may
bias associations towards the null, making intent-to-treat results
difficult to interpret. We had not originally anticipated that early
weaning would be so poorly accepted in our study population. The
secondary analysis we present here is, like all analyses of
epidemiological data, vulnerable to confounding and reverse
causation. To address reverse causation, we reviewed the
circumstances of all deaths, and weaning was only classified to
have occurred if breastfeeding had ceased before the illness that
preceded the child’s death, and not as a result of that illness. We
acknowledge that this cannot be foolproof but our approach avoids
one of the methodological problems that has been previously
identified in the field of breastfeeding research [23]. We also
examined a large number of confounders, including several known
to be strong predictors of HIV transmission, specifically maternal
Characteristic Total N N (%) stopped BF by end of 4 mo p-value
Full-/part-time or informal sector job 98 69 (69.7)
Unemployed 229 134 (58.5) 0.06
Child characteristics:
Infant sex
Male 175 104 (59.4)
Female 153 99 (64.7) .0.10
Birth weight
,2,500 grams 28 19 (67.9)
$2,500 grams 294 182 (61.9) .0.10
*Less severe disease was defined as CD4 counts .350 cells/mL during pregnancy or if between 200 and 349 cells/mL had to be classified as WHO stage II or less; more
severe disease was defined as CD4 count ,200 cells/mL or if CD4 count 200–349 cells/mL had to be classified as WHO stage III or greater.
doi:10.1371/journal.pone.0006059.t001
Table 1. Cont.
HIV-Free Survival and Weaning
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of child mortality, namely birth weight and socioeconomic standing.
None of these factors explained away the weaning associations.
However, it is possible that other unmeasured confounders may
account for our associations. The associations between weaning and
adverse outcomes were consistent across the intervention and
control groups. This makes it highly unlikely that social desirability
tendencies or reporting biases (which would operate in different
directions in the two groups) would explain the findings. Moreover,
the benefits of continued breastfeeding in the women without
advanced HIV disease are similar to those reported in non HIV
infected populations [24].
Conclusions
Current WHO guidelines encourage weaning to occur only
once affordable, feasible, acceptable, sustainable, and safe
(AFASS) alternatives to breast milk are available [25]. If
guidelines are followed, HIV-infected women would only have
initiated breastfeeding if AFASS criteria were not met during
pregnancy. Since socioeconomic circumstances are unlikely to
change between pregnancy and 6 months, it is unclear what this
recommendation means for the appropriate age of weaning.
Using HIV-free survival as the outcome, our data demonstrate
that women from urban, resource-limited settings, who have high
CD4 counts, place their infants at significantly increased risk if
breastfeeding is stopped at any time before 16 months. There is a
net benefit of continued breastfeeding for HIV-free survival of
infants when maternal CD4 counts exceed about 300 cells/ul.
For women with lower CD4 counts, initiating ART as
expeditiously as possible during pregnancy should be an urgent
priority, for their own health and to reduce transmission to the
child.
Figure 1. Panel A: HIV-free survival among 229 children in the intervention group whose mothers had less severe disease and
would not have been eligible for antiretroviral therapy during pregnancy stratified by whether they adhered to the intervention
(weaned by the completion of 4 months) (dashed line) or whether they continued breastfeeding after 4 months (solid line)
(p=0.035). Panel B: HIV-free survival among 97 children in the intervention group whose mothers had advanced disease and would have been
eligible for antiretroviral therapy during pregnancy but did not receive it stratified by whether they adhered (weaned by the completion of 4 months)
(dashed line) or whether they continued breastfeeding after 4 months (solid line) (p=0.006).
doi:10.1371/journal.pone.0006059.g001
HIV-Free Survival and Weaning
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PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e6059Table 3. Predictors of breast feeding duration among 333 mother-child pairs randomized to the control group surviving HIV-free
and still breastfeeding at 4 months.
Characteristic Total N Median duration BF (months) p-value
Maternal factors:
CD4 count
,200 64 15.0
200–349 95 16.0
$350 cells/mm
3 174 17.0 .0.10
Plasma viral load
#9,999 99 16.0
10,000–99,999 155 16.0
$100,000 copies/ml 78 17.0 .0.10
Hemoglobin
,10 88 16.0
$10 g/dL 238 16.0 .0.10
Classification of severity of disease*
Less severe 228 17.0
More severe 105 15.2 .0.10
Body mass index 1 month post-partum
,18.5 44 17.0
$18.5 288 16.0 .0.10
Age (years)
,20 28 15.0
20–24 111 16.0
25–29 107 17.0
$30 87 16.0 .0.10
Parity
First child 43 15.3
2
nd–3
rd 151 16.0
$Fourth 139 17.0 .0.10
RPR status
Positive 55 18.0
Negative 255 16.0 .0.10
Social factors:
Disclosed HIV status to partner 198 16.0
Not disclosed 135 16.5 .0.10
Marital status
Married 281 16.0
Single 33 14.0
Widowed/divorced/separated 19 17.0 .0.10
Education
No school or ,8 years of school 177 17.3
Some or complete high school ($8 y) 156 15.0 0.004
Domestic water source
Within dwelling or on property 51 15.0
Communal 282 16.7 0.007
Electricity in the home
Yes 134 15.0
No 199 17.0 0.002
Cooking facilities
Stove/hotplate 117 15.0
Charcoal/wood 215 17.0 0.0002
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PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e6059Characteristic Total N Median duration BF (months) p-value
Full-/part-time or informal sector job 110 16.0
Unemployed 223 16.0 .0.10
Child characteristics:
Infant sex
Male 174 17.0
Female 158 16.0 .0.10
Birth weight
,2,500 grams 34 18.0
$2,500 grams 293 16.0 .0.10
*Less severe disease was defined as CD4 counts .350 cells/mL during pregnancy or if between 200 and 349 cells/mL had to be classified as WHO stage II or less; more
severe disease was defined as CD4 count ,200 cells/mL or if CD4 count 200–349 cells/mL had to be classified as WHO stage III or greater.
doi:10.1371/journal.pone.0006059.t003
Table 3. Cont.
Table 4. Effects of weaning before 15 months on the combined outcome of HIV transmission or uninfected child mortality
stratified by the severity of maternal HIV disease in the intervention and control groups separately.
Maternal disease status during pregnancy* Intervention Group Control Group
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Less severe
Stop BF #15 months 3.34 (1.16–9.59) 0.025 3.94 (1.65–9.39) 0.002
More severe
Stop BF #15 months 0.24 (0.07–0.85) 0.027 0.72 (0.23–2.29)
p-value interaction 0.001 0.01
*Less severe disease was defined as CD4 counts .350 cells/mL during pregnancy or if between 200 and 349 cells/mL had to be classified as WHO stage II or less; more
severe disease was defined as CD4 count ,200 cells/mL or if CD4 count 200–349 cells/mL had to be classified as WHO stage III or greater.
{Hazard ratios are from Cox Proportional Hazards models treating breast feeding cessation before 15 months as a time-dependent covariate adjusting for maternal viral
load, hemoglobin, body mass index, parity and child birth weight. Hazard ratios .1 indicate that weaning increases the risk of the combined outcome of HIV infection
or death. Hazard ratios ,1 indicate that weaning decreases the risk of the outcome.
doi:10.1371/journal.pone.0006059.t004
Figure 2. Relative hazards of HIV infection or death by weaning before 15 completed months stratified by maternal CD4 count
during pregnancy. Hazard ratios greater than 1 indicate that weaning increases the risk of HIV/death. Hazard ratios less than 1 indicate that
weaning decreases the risk of HIV/death.
doi:10.1371/journal.pone.0006059.g002
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